TMCI — Treace Medical Concepts, Inc.

TMCI Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: $50.2 million, an 11% increase year-over-year.
• Adjusted EBITDA: Loss of $2.6 million, a 49% improvement from a loss of $5.1 million in Q3 2024.
• Net Loss: $16.3 million ($0.26 per share), compared to a net loss of $15.4 million ($0.25 per share) in Q3 2024.
• Gross Margin: 79.1%, down from 80.1% in Q3 2024.
• Operating Expenses: $55.4 million, an 8% increase from $51.3 million in Q3 2024.
• Liquidity: $80.6 million as of September 30, 2025, down from $90.7 million at the end of Q2 2025.

2. Strategic Updates and Business Highlights

• Transitioning from a single technology focus (Lapiplasty) to a comprehensive bunion solutions provider, now offering five instrumented systems for bunion correction.
• Launched three new bunion correction systems, aiming to capture a broader surgeon audience.
• Appointed a new Chief Commercial Officer and expanded the sales team to enhance market presence.
• Experienced mid-single-digit case volume growth, primarily driven by new bunion systems with lower average selling prices (ASPs).

3. Forward Guidance and Outlook

• Revised Revenue Guidance: Expected full-year 2025 revenue between $211 million and $213 million, representing 1% to 2% growth compared to 2024.
• Adjusted EBITDA Loss: Projected to be between $6.5 million and $7.5 million for 2025, indicating a 32% to 41% improvement year-over-year.
• Cash Usage: Anticipated reduction of 43% to 47% for 2025 compared to 2024.

4. Bad News, Challenges, or Points of Concern

• Declining Lapiplasty Volumes: Noted pressure on Lapiplasty sales due to a shift in surgeon and patient preferences towards minimally invasive osteotomies.
• Deferred Elective Procedures: Broader economic conditions and consumer sentiment have led to increased deferrals of elective bunion surgeries, impacting case volumes.
• Stocking Distributor Sales: A significant portion of Q3 revenue was driven by stocking distributor sales, which are not expected to recur at the same level in Q4.
• Market Dynamics: Survey results indicated a 7% decrease in bunion surgical volumes year-to-date among surveyed surgeons, reflecting broader market challenges.

5. Notable Q&A Insights

• Surgeon Preferences: The shift towards minimally invasive procedures is impacting Lapiplasty sales, but management believes they can capture market share in this area with new technologies.
• Future Growth: Management is optimistic about increasing case volumes and adoption of new products, which could help offset declines in Lapiplasty.
• Cost Management: The company is actively seeking efficiencies and restructuring to manage costs amid lower-than-expected revenue growth.
• 2026 Outlook: While not providing specific guidance, management expressed confidence in their ability to recapture deferred procedures and improve market share with their expanded product offerings.

Overall, TMCI is navigating a challenging market environment but is focused on leveraging its expanded product portfolio and sales capabilities to drive future growth.